Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2003 1
2006 1
2007 1
2008 4
2009 3
2010 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Nevirapine concentrations in newborns receiving an extended prophylactic regimen.
Mirochnick M, Nielsen-Saines K, Pilotto JH, Pinto J, Jiménez E, Veloso VG, Parsons T, Watts DH, Moye J, Mofenson LM, Camarca M, Bryson Y; NICHD/HPTN 040/PACTG 1043 Protocol Team. Mirochnick M, et al. J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):334-7. J Acquir Immune Defic Syndr. 2008. PMID: 18398973 Clinical Trial.
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Hicks CB, DeJesus E, Sloan LM, Sension MG, Wohl DA, Liao Q, Ross LL, Pakes GE, Pappa KA, Lancaster CT; COL100758 Study Team. Hicks CB, et al. Among authors: lancaster ct. AIDS Res Hum Retroviruses. 2009 Apr;25(4):395-403. doi: 10.1089/aid.2008.0231. AIDS Res Hum Retroviruses. 2009. PMID: 19320570 Clinical Trial.
Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers.
Ruane PJ, Luber AD, Wire MB, Lou Y, Shelton MJ, Lancaster CT, Pappa KA; COL10053 Study Team. Ruane PJ, et al. Among authors: lancaster ct. Antimicrob Agents Chemother. 2007 Feb;51(2):560-5. doi: 10.1128/AAC.00560-06. Epub 2006 Nov 6. Antimicrob Agents Chemother. 2007. PMID: 17088488 Free PMC article. Clinical Trial.
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Ross LL, Weinberg WG, DeJesus E, Fischl MA, Horton JH, Pappa KA, Lancaster CT, Pakes GE, Smith KY. Ross LL, et al. Among authors: lancaster ct. AIDS Res Hum Retroviruses. 2010 Apr;26(4):407-17. doi: 10.1089/aid.2009.0189. AIDS Res Hum Retroviruses. 2010. PMID: 20380480 Free PMC article. Clinical Trial.
Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Nadler JP, Gathe JC, Pollard RB, Richmond GJ, Liao Q, Griffith S, Lancaster CT, Hernandez JE, Pappa KA; ESS40011 (STARR) Study Team. Nadler JP, et al. Among authors: lancaster ct. BMC Infect Dis. 2003 Jun 10;3:10. doi: 10.1186/1471-2334-3-10. BMC Infect Dis. 2003. PMID: 12795812 Free PMC article. Clinical Trial.
11 results